Isolated limb infusion: A review

Kroon, Hidde M.; Thompson, John F.

doi:10.1002/jso.21280

Cited by 43 publications

(35 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, there is no definitive proof supporting the advantage of HIPEC over normothermic IPCP, and accumulating preclinical data suggest that HIPEC has no advantage over IPCP (22)(23)(24). Hyperthermia has already been proven to be of no value in isolated limb chemoperfusion (25). IPCP is associated with the inherent toxicity of chemotherapy and additional toxicity due to damage of the peritoneum (26) and septic shock (27).…”

Section: Introductionmentioning

confidence: 99%

Local modulated electro-hyperthermia in combination with traditional Chinese medicine vs. intraperitoneal chemoinfusion for the treatment of peritoneal carcinomatosis with malignant ascites: A phase II randomized trial

Pang¹,

Zhang²,

Wang³

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The purpose of this study was to develop a safe and non-toxic alternative to the conventional conservative treatment of peritoneal carcinomatosis with malignant ascites (PCMA) by investigating the efficacy and safety of local modulated electro-hyperthermia (mEHT) combined with the traditional Chinese medicine (TCM) 'Shi Pi' herbal decoction, compared with standard intraperitoneal chemoinfusion (IPCI). A randomized, controlled, single-center, open-label clinical trial (phase II) with two parallel groups (allocation ratio, 1:1) was conducted to investigate the efficacy and safety of mEHT+TCM (study group, SG) vs. standard IPCI (control group, CG) in patients with PCMA by intention-to-treat analysis. A total of 260 patients with PCMA were randomly allocated into the two groups (130/130); mEHT was applied for 60 min per session every second day for 4 weeks, for a total of 14 sessions. The TCM decoction was administered orally, at 400 ml daily. In CG, occlusive IPCI with cisplatin (30-60 mg) and fluorouracil (500-600 mg/m 2 ) was applied twice, biweekly. The objective response rate (ORR), quality of life (QoL) and adverse event rate (AER) in the two groups were evaluated 1 month after treatment, analyzed and compared. The present study is registered on ClinicalTrials.gov (NCT02638051). No case was lost or excluded (0/260). The ORR in SG was 77.69% (101/130) vs. 63.85% (73/130) in CG (P<0.05). The QoL in SG was 49.23% vs. 32.3% in CG (P<0.05). The AER in SG was 2.3% (3/130) vs. 12.3% (16/130) in CG (P<0.05). All the adverse events were grade I. In conclusion, the combination of mEHT with TCM achieves better control of PCMA compared with standard IPCI, with less toxicity. Both components of the combination are non-toxic treatments easily tolerated by patients. Thus, this combined treatment may be preferred due to the better benefit-harm balance.

show abstract

Section: Introductionmentioning

confidence: 99%

Local modulated electro-hyperthermia in combination with traditional Chinese medicine vs. intraperitoneal chemoinfusion for the treatment of peritoneal carcinomatosis with malignant ascites: A phase II randomized trial

Pang¹,

Zhang²,

Wang³

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Patients with multiple (inoperable) metastases to (only) one extremity may be suitable for intensive local chemotherapy (isolated limb perfusion) (17). Hyperthermia is applied together with intra-arterial melphalan hydrochloride, either alone or in combination with tumour necrosis factor (TNF).…”

Section: Local Chemotherapymentioning

confidence: 99%

Malignt melanom – diagnostikk, behandling og oppfølging i Norge

Geisler¹,

Bachmann²,

Nyakas³

et al. 2013

Tidsskriftet

View full text Add to dashboard Cite

BACKGROUND The incidence of malignant melanoma in Norway is among the highest in the world and rising, with approximately 1 500 persons receiving the diagnosis annually. Correct surgical primary treatment cures 80 -90 %, while 10 -20 % experience relapses. The treatment of a metastatic malignant melanoma has changed considerably in the last 1 -2 years as a result of clinical experience with new drugs. The current publication provides an updated overview of the treatment of malignant melanoma in Norway.

show abstract

“…Most commonly, agents used for soft tissue sarcoma of the extremity include tumor necrosis factor-alpha (TNF-), melphalan, doxorubicin, cisplatin, carboplatin and actinomycin-D (Hoekstra 2008;Kroon & Thompson 2009). TNF- is only available in Europe.…”

Section: Wwwintechopencommentioning

confidence: 99%